Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.

Blood Cancer J · 2023 · PMC10514257 · PMID 37735426

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

There was an observed trend towards a longer mOS in patients who switched from VEN + HMA to a VEN + HMA + IDHi triplet rather than a subsequent IDHi doublet or monotherapy (Supplemental Fig. 6 ).

also in 200 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.